Prostate

• 

  Publication Venue For

  • Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH..  77:1592-1600. 2017
  • Association of Obesity-Related Hemodilution of Prostate-Specific Antigen, Dihydrotestosterone, and Testosterone..  77:466-470. 2017
  • Number of Unfavorable Intermediate-Risk Factors Predicts Pathologic Upstaging and Prostate Cancer-Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database..  77:154-163. 2017
  • Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes.  75:463-473. 2015
  • Patient preferences for treatments to delay bone metastases..  74:1488-1497. 2014
  • Enrichment of putative prostate cancer stem cells after androgen deprivation: Upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines.  73:1378-1390. 2013
  • Characteristics of baseline PSA and PSA velocity in young men without prostate cancer: Racial differences..  72:173-180. 2012
  • Emerging treatment options for patients with castration-resistant prostate cancer..  72:338-349. 2012
  • PC3 is a cell line characteristic of prostatic small cell carcinoma.  71:1668-1679. 2011
  • Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer.  69:787-798. 2009
  • Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes.  68:839-848. 2008
  • Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis..  68:11-19. 2008
  • Genome-wide linkage of 77 families from the African American Hereditary Prostate Cancer study (AAHPC)..  67:22-31. 2007
  • Immunohistochemical characterization of neuroendocrine cells in prostate cancer.  66:1399-1406. 2006
  • Lysophosphatidic acid promotes survival of androgen-insensitive prostate cancer PC3 cells via activation of NF-kappaB..  61:105-113. 2004
  • Selenomethionine does not affect PSA secretion independent of its effect on LNCaP cell growth..  54:315-321. 2003
  • Inhibition of human chorionic gonadotropin beta-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells..  53:200-210. 2002
  • Insulin-like growth factor binding protein-3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo..  51:141-152. 2002
  • Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin..  48:71-78. 2001
  • Reduced expression of hMSH2 and hMLH1 and risk of prostate cancer: a case-control study..  47:269-275. 2001
  • Rational basis for Trk inhibition therapy for prostate cancer..  45:140-148. 2000
  • Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers..  42:295-303. 2000
  • Mutational analysis of the TrkA gene in prostate cancer..  36:172-180. 1998
  • Prostate-specific antigen-detected prostate cancer (stage T1c): an analysis of whole-mount prostatectomy specimens..  32:59-64. 1997
  • Mutations of the p16 gene product are rare in prostate cancer..  30:188-194. 1997
  • 6-Methylene progesterone is cytotoxic to human cancer cell lines independent of its 5-alpha-reductase activity..  26:28-34. 1995
  • A coaxial microwave applicator for transurethral hyperthermia of the prostate..  22:125-138. 1993
  • Infrequent RAS oncogene mutations in human prostate cancer..  20:327-338. 1992
  • Establishment of a long‐term adenocarcinoma of the prostate cell line in the nude mouse.  7:369-376. 1985
  • A serologic approach to the definition of human prostatic carcinoma antigens..  2:369-380. 1981